HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Given Consensus Rating of “Hold” by Analysts

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) has been given an average rating of “Hold” by the six analysts that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $20.8750.

A number of research analysts have commented on HCM shares. Wall Street Zen cut shares of HUTCHMED from a “buy” rating to a “hold” rating in a research note on Saturday. Weiss Ratings restated a “hold (c)” rating on shares of HUTCHMED in a report on Thursday, January 22nd. Finally, Jefferies Financial Group raised shares of HUTCHMED to a “strong-buy” rating in a research report on Monday, January 19th.

Institutional Trading of HUTCHMED

Institutional investors and hedge funds have recently bought and sold shares of the business. Jane Street Group LLC lifted its stake in shares of HUTCHMED by 128.0% during the 1st quarter. Jane Street Group LLC now owns 222,241 shares of the company’s stock worth $3,343,000 after buying an additional 124,771 shares during the last quarter. UBS Group AG boosted its holdings in shares of HUTCHMED by 112.8% during the third quarter. UBS Group AG now owns 137,000 shares of the company’s stock worth $2,158,000 after acquiring an additional 72,614 shares during the period. Amundi grew its position in shares of HUTCHMED by 41.9% in the third quarter. Amundi now owns 223,330 shares of the company’s stock valued at $3,620,000 after purchasing an additional 65,898 shares during the last quarter. ABN Amro Investment Solutions acquired a new stake in HUTCHMED during the 2nd quarter worth approximately $962,000. Finally, M&G PLC boosted its stake in HUTCHMED by 26.7% in the 4th quarter. M&G PLC now owns 259,033 shares of the company’s stock valued at $3,367,000 after purchasing an additional 54,601 shares during the period. Institutional investors own 8.82% of the company’s stock.

HUTCHMED Price Performance

Shares of HUTCHMED stock opened at $13.85 on Monday. HUTCHMED has a 12 month low of $11.51 and a 12 month high of $19.50. The company has a quick ratio of 4.51, a current ratio of 4.65 and a debt-to-equity ratio of 0.05. The firm’s fifty day simple moving average is $14.71 and its 200-day simple moving average is $14.97.

HUTCHMED (NASDAQ:HCM) last posted its quarterly earnings data on Thursday, March 5th. The company reported $0.01 EPS for the quarter, missing analysts’ consensus estimates of $2.50 by ($2.49). The company had revenue of $135.42 million during the quarter, compared to analyst estimates of $290.50 million. As a group, analysts anticipate that HUTCHMED will post 0.16 earnings per share for the current year.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.